Статья
Первичная ангиопластика и фармакоинвазивный подход в лечении инфаркта миокарда с подъемом сегмента ST на электрокардиограмме
Лекция посвящена выбору тактики и правилам реперфузионной терапии при инфаркте миокарда с подъемом ST на электрокардиограмме. Поскольку время реперфузии является критически важным для выживаемости пациентов и сохранения жизнеспособного миокарда, необходима правильная организация оказания помощи и четкое следование рекомендациям при медикаментозных и немедикаментозных вмешательств. В лекции обоснованы тактика фармакоинвазивного вмешательства, выбор тромболитического агента, представлена информация о показаниях и противопоказаниях к тромболитической терапии, режим дозирования тромболитических средств, других антиагрегантных и антикоагулянтных препаратов, необходимых при репефузии. Знание современных рекомендаций должно способствовать сокращению времени ишемии и случаев необоснованного отказа от эффективных вмешательств.
1. Клинические рекомендации Диагностика и лечение больных острым инфарктом миокарда с подъемом сегмента ST ЭКГ Кардиоваскулярная терапия и профилактика. 2007;6(8), Приложение 1.
2. Скорая медицинская помощь. Клинические рекоменда-ции/под ред. С. Ф. Багненко. М.: ГЭОТАР-Медиа, 2015. 872 с. ISBN 978-5-97043447-5.
3. Ibanez B, James S, Agewall S, et al. ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018;39(2):119-77 doi:10.1093/eurheartj/ehx393.
4. Danchin N, Coste P, Ferrieres J, et al. Comparison of thrombolysis followed by broad use of percutaneous coronary intervention with primary percutaneous coronary intervention for ST-segment-elevation acute myocardial infarction. Data from the French Registry on Acute ST-Elevation Myocardial Infarction (FAST-MI). Circulation. 2008;118(3):268-76. doi:10.1161/CIRCULATIONAHA.107762765.
5. Васильева Е. Ю., Плавунов Н. Ф., Калинская А. И. и др. Организация “инфарктной сети” в Москве и результаты ее работы за пятилетний период. Эндоваскулярная хирургия. 2018;5(2):288-94.
6. Барбараш О. Л., Кашталап В. В. Место фармакоинвазивной тактики ведения пациентов с острым коронарным синдромом с подъемом сегмента ST в России. Кардиология. 2014;54(9):79-85.
7. Артамонова Г. В., Херасков В. Ю., Крючков Д.В и др. Подход к организации помощи больным с инфарктом миокарда — “кемеровская модель”. Компл пробл сердечно-сосудистых забол. 2013;1:55-9.
8. . Бокерия Л. А., Ключников И. В., Чигогидзе Н. А. и др. Влияние срока после тромболитической терапии на результаты стентирования коронарных артерий у больных с инфарктом миокарда. Бюл НЦССХ им. А.Н. Бакулева РАМН. 2013;6:46-50.
9. Pinto DS, Frederick PD, Chakrabarti AK, et al, National Registry of Myocardial Infarction Investigators. Benefit of transferring ST-segment-elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. Circulation. 2011;124(23):2512-21. doi:10.1161/CIRCULATIONAHA.111.018549.
10. Armstrong PW, Gershlick AH, Goldstein P, et al. STREAM Investigative Team. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368(15):1379-87. doi:10.1056/NEJMoa1301092.
11. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343(8893):311-22. doi:10.1016/S0140-6736(94)91161-4.
12. Boersma E, Maas AC, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996 Sep 21;348(9030):771-5. doi:10.1016/S0140-6736(96)02514-7.
13. White HD. Thrombolytic therapy in the elderly. Lancet. 2000;356(9247):2028-30. doi:10.1016/S0140-6736(00)03397-3.
14. Carville S, Harker M, Henderson R, Gray H. Guideline Development Gro Acute management of myocardial infarction with ST-segment elevation: summary of NICE guidance. BMJ. 2013 Jul 10;347:f4006. doi:10.1136/bmj.f4006.
15. O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. JACC. 2013;61(4):e78-140. doi:10.1016/j.jacc.2012.11.019.
16. Danchin N, Blanchard D, Steg PG, et al.; USIC 2000 Investigators. Impact of prehospital thrombolysis for acute myocardial infarction on 1-year outcome: results from the French Nationwide USIC 2000 Registry. Circulation. 2004;110:1909-15. doi:10.1161/01.CIR.0000143144.82338.36.
17. Murphy SA, Gibson CM, Van de Werf F, et al. Comparison of errors in estimating weight and in dosing of single-bolus tenecteplase with tissue plasminogen activator (TIMI 10B and ASSENT I). Am J Cardiol. 2002;90(1):51-4. doi:101016/S0002-9149(02)02387-1.
18. Armstrong PW, Zheng Y, Westerhout CM, et al. STREAM investigators. Reduced dose tenecteplase and outcomes in elderly ST-segment elevation myocardial infarction patients: Insights from the STrategic Reperfusion Early After Myocardial infarction trial. Am Heart J. 2015;169(6):890-8.e1. doi:10.1016/j.ahj.2015.03.011.
19. Lanaro E, Caixeta A, Soares JA, et al. Influence of gender on the risk of death and adverse events in patients with acute myocardial infarction undergoing pharmacoinvasive strategy. J Thromb Thrombolysis. 2014;38(4):510-6. doi:101007/s11239-014-1072-7.
20. Bainey KR, Ferguson C, Ibrahim QI, et al. Vital Heart Response Registry Investigators. Impact of reperfusion strategy on aborted myocardial infarction: insights from a large Canadian ST-Elevation Myocardial Infarction Clinical Registry. Can J Cardiol. 2014;30(12):1570-5. doi:10.1016/j.cjca.2014.08.021.
21. Dianati Maleki N, Van de Werf F, Goldstein P, et al. Aborted myocardial infarction in ST-elevation myocardial infarction: insights from the STrategic Reperfusion Early After Myocardial infarction trial. Heart. 2014;100(19):1543-9. doi:10.1136/heartjnl-2014-306023.
22. Shavadia J, Zheng Y, Dianati Maleki N, et al. Infarct Size, Shock, and Heart Failure: Does Reperfusion Strategy Matter in Early Presenting Patients With ST-Segment Elevation Myocardial Infarction? J Am Heart Assoc. 2015;4(8):e002049. doi: 10.1161/JAHA.115.002049.
23. Bundhun PK, Janoo G, Chen MH. Bleeding events associated with fibrinolytic therapy and primary percutaneous coronary intervention in patients with STEMI: A systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2016;95(23): e3877. doi:10.1097/MD.0000000000003877.
24. Guillermin A, Yan DJ, Perrier A, Marti C. Safety and efficacy of tenecteplase versus alteplase in acute coronary syndrome: a systematic review and meta-analysis of randomized trials. Arch Med Sci. 2016;12(6):1181-7. doi:10.5114/aoms.2016.58929.
25. Liu F, Guo Q, Xie G, et al. Percutaneous Coronary Intervention after Fibrinolysis for ST-Segment Elevation Myocardial Infarction Patients: An Updated Systematic Review and Meta-Analysis. PLoS One. 2015;10(11):e0141855. doi:10.1371/journal.pone.0141855.
26. Jaffe R, Halon DA, Karkabi B, et al. Thrombolysis Followed by Early Revascularization: An Effective Reperfusion Strategy in Real World Patients with ST-Elevation Myocardial Infarction Cardiology. 2007;107:329-36. doi:10.1159/000099070.
27. Rashid MK, Guron N, Bernick J, et al. Safety and Efficacy of a Pharmacoinvasive Strategy in ST-Segment Elevation Myocardial Infarction: A Patient Population Study Comparing a Pharmacoinvasive Strategy With a Primary Percutaneous Coronary Intervention Strategy Within a Regional System. JACC Cardiovasc Interv. 2016;9(19): 2014-20. doi:10.1016/j.jcin.2016.07.004.
28. Sim DS, Jeong MH, Ahn Y, et al. Korea Acute Myocardial Infarction Registry (KAMIR) Investigators. Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in Patients With ST-Segment-Elevation Myocardial Infarction: A Propensity Score-Matched Analysis. Circ Cardiovasc Interv. 2016;9(9). pii:e003508. doi:10.1161/CIRCINTERVENTIONS.115.003508.
29. Pu J, Ding S, Ge H, et al. EARLY-MYO Investigators. Efficacy and Safety of a Pharmaco-Invasive Strategy With Half-Dose Alteplase Versus Primary Angioplasty in ST-Segment-Elevation Myocardial Infarction: EARLY-MYO Trial (Early Routine Catheterization After Alteplase Fibrinolysis Versus Primary PCI in Acute ST-Segment-Elevation Myocardial Infarction). Circulation. 2017;136(16):1462-73. doi:10.1161/CIRCULATIONAHA.117.030582.
30. Pinto DS, Kirtane AJ, Nallamothu BK, et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation. 2006;114:2019-25. doi:10.1161/CIRCULATIONAHA.106.638353.
31. Siddiqi TJ, Usman MS, Khan MS, et al. Meta-Analysis Comparing Primary Percutaneous Coronary Intervention Versus Pharmacoinvasive Therapy in Transfer Patients with ST-Elevation Myocardial Infarction. Am J Cardiol. 2018;122(4):542-7. doi:10.1016/j.amjcard.2018.04.057.
32. Berwanger O, Nicolau JC, Carvalho AC, et al. Ticagrelor versus clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: Rationale and design of the ticagrelor in patients with ST elevation myocardial infarction treated with thrombolysis (TREAT) trial. Am Heart J. 2018;202:89-96. doi:10.1016/j.ahj.2018.02.017.